Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Phase 2: Self-reported clinical characteristics

From: Understanding side effects of therapy for myasthenia gravis and their impact on daily life

CharacteristicOverall Sample (N = 242) n (%)
In which of the following areas have you ever experienced myasthenia gravis symptoms?1
 Eye muscles218 (90.1%)
 Chewing, swallowing, speaking206 (85.1%)
 Neck, arm, and legs198 (81.8%)
 Breathing149 (61.6%)
 Other42 (17.4%)
In the past month, where have you experienced myasthenia gravis symptoms?1
 Eye muscles150 (62.0%)
 Chewing, swallowing, speaking139 (57.4%)
 Neck, arm, and legs137 (56.6%)
 Breathing87 (36.0%)
 Other50 (20.7%)
Current medication(s)/procedures for myasthenia gravis1
 Pyridostigmine167 (69.0%)
 Oral corticosteroids82 (33.9%)
 Mycophenolate mofetil61 (25.2%)
 Intravenous immunoglobulin (IVIg)57 (23.6%)
 Azathioprine52 (21.5%)
 Plasma exchange14 (5.8%)
 Rituximab13 (5.4%)
 Methotrexate7 (2.9%)
 Cyclophosphamide1 (0.4%)
 Tacrolimus1 (0.4%)
 Other21 (8.7%)
 None15 (6.2%)
Medication(s) ever taken for myasthenia gravis1
 Oral corticosteroids101 (41.7%)
 Pyridostigmine99 (40.9%)
 Intravenous immunoglobulin (IVIg)73 (30.2%)
 Azathioprine65 (26.9%)
 Plasma exchange57 (23.6%)
 Mycophenolate mofetil55 (22.7%)
 Rituximab15 (6.2%)
 Cyclosporine A11 (4.5%)
 Methotrexate7 (2.9%)
 Neostigmine6 (2.5%)
 Cyclophosphamide3 (1.2%)
 Other9 (3.7%)
 None41 (16.9%)
Previous thymectomy (% yes)91 (37.6%)
  1. 1Not mutually exclusive